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Highly active anti-retroviral treatment (HAART) targets less than a third of the proteins 
produced during HIV-1 infection. Testing the effectiveness of an anti-retroviral drug requires 
assays specific for the individual target that take into account its mechanism of action. Most 
HIV-1 proteins need to undergo dimerization in order to become functional in the viral life cycle. 
Historically, it has been difficult to visualize and quantify changes in a protein-protein 
interaction, which has left this characteristic of proteins unexplored as potential antiviral targets. 
In this study, a bimolecular fluorescence complementation based screening assay is developed 
that can quantify a change in dimerization, using the HIV-1 accessory protein Vpr as a “proof of 
concept”.   
 
Results demonstrated that bimolecular fluorescence complementation of Vpr could be competed 
off in a dose-dependent manner using untagged, full length Vpr as a competitor molecule. The 
change in signal intensity was measured quantitatively through flow cytometry and fluorescence 
microscopy in a high content screening assay.  High content imaging was used to screen a library 
of peptides and a library of small molecules for an effect on Vpr dimerization. None of the Vpr 
peptides were shown to have an effect; however, one of the small molecules was shown to 
interfere with Vpr dimerization in a dose-dependent manner. 
Velpandi Ayyavoo, PhD 
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Statement of Public Health relevance: Dimerization is a unique property of many HIV-1 viral 
proteins and is necessary to complete the viral life cycle, thus it has been identified as a potential 
drug target. By developing an assay that screens for inhibition of HIV-1 protein dimerization, 
high throughput screening can be performed to detect inhibitors of a new target in HIV-1 
replication. Small molecules identified using this screening method could be developed into a 
novel anti-retroviral drug. 
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1.0  INTRODUCTION 
1.1 THE AIDS EPIDEMIC 
There are currently an estimated 33.3 million people infected worldwide with HIV/AIDS 
(Human Immunodeficiency Syndrome / Acquired Immune Deficiency Syndrome) [1]. The 
causative agent for this disease is the human immunodeficiency virus. The yearly AIDS-related 
mortality has declined for the past 5 years due to the availability of highly active anti-retroviral 
therapy (HAART). Before HAART was available, a diagnosis of HIV-1 resulted in death in 
approximately 12 years from diagnosis [2].  In the United States, HAART has extended the lives 
of HIV patients by an estimated 30 years, transforming HIV/AIDS into a chronic condition [3]. 
This switch from fatal disease to chronic infection has led to development of anti-retrovirals that 
emphasize decreased toxicity and side effects [4].  
 
Five major classes of antiretroviral therapy are currently prescribed, including entry inhibitors 
and specific inhibitors of three HIV proteins (Table 1). Generally, HAART is administered as 
combination therapy consisting of two nucleoside reverse transcriptase inhibitors and either a 
protease inhibitor or a non-nucleoside reverse transcriptase inhibitor [5]. Unfortunately, these 
therapies frequently lead to side effects, including cardiovascular disease, neurocognitive 
impairment, hepatotoxicity, and changes in lipid metabolism and fat deposition [6]. These can be 
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so severe that "structured treatment interruptions" have been used in an attempt to alleviate 
toxicity [7].  
Table 1: Current classes of antiretroviral drugs. 
 
Treatment interruption poses serious risks to the overall success of HAART. The high mutation 
rate of the HIV-1 virus fosters the development of drug-resistant strains. Rigorous adherence to 
therapy is necessary to control viral infection; missing a single day over the course of a month 
increases the risk of treatment failure six-fold [8]. Even with strict adherence to the drug 
regimen, 5% of patients on HAART develop drug resistance within the first year of therapy [9]. 
Treatment interruptions have been discontinued as a therapeutic option due to the increased risk 
of developing drug resistant viral strains. 
 
Current antiretroviral therapy provides a treatment, not a cure, for HIV/AIDS. Even in the 
absence of treatment failure, viral reservoirs such as macrophages and resting T cells prevent 
total viral clearance even during an extensive HAART regimen [10-12]. The development of 
drug-resistant viral strains leads contributes to treatment failure of individual drugs and/or entire 
drug classes [13].  New members of existing drug classes are sought that minimize the harmful 
Class Target Inhibition  Mechanism 
Nucleoside 
RT inhibitors Reverse 
Transcriptase 
Competitive Chain termination of new DNA strand 
Non-Nucleoside 
RT inhibitors 
Non-competitive Inactivation of RT enzyme 
Protease 
inhibitors 
Protease Competitive Block  generation of mature proteins 
Integrase 
inhibitors 
Integrase Non-competitive Block strand transfer 
Entry 
inhibitors 
Co-receptor Competitive Prevent binding of virus to uninfected cell 
Fusion Non-competitive Prevent virus from crossing cell membrane 
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side effects of long-term antiretroviral therapy and that provide alternatives that restore drug 
activity in the face of drug resistant HIV-1 strains [14-16]. In addition to new members of 
existing anti-retroviral drug classes, investigators have begun to develop therapies against 
additional viral proteins and interactions between the virus and the host cell [17-23]. These novel 
targets could provide more options for salvage therapy after HAART failure and improve the 
overall efficacy of HIV therapy. 
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2.0  BACKGROUND 
2.1 HUMAN IMMUNODEFICIENCY VIRUS 
The human immunodeficiency virus type 1 (HIV-1) is a member of the Retroviridae family 
belonging to the genus Lentiviridae. It is an enveloped virus containing two copies of its single-
stranded RNA genome. Like most members of the retrovirus family, it uses gag, pol, and env 
genes to encode its structural and enzymatic proteins. HIV-1 also encodes two regulatory 
proteins (Tat and Rev), and four accessory proteins (Vif, Vpr, Vpu, and Nef) (Figure 1).  
 
Figure 1: The HIV genome. The HIV genome includes both structural and accessory genes and is flanked on both 
ends by the HIV-1 LTR (long terminal repeat) promoter region. 
 
The structural and regulatory proteins of HIV-1 each have a single function in the HIV life cycle 
[24]. The structural genes gag, pol and env encode polyproteins with multiple subunits. The Gag 
polyprotein is composed of matrix, capsid and nucleocapsid, the structural proteins of the virion. 
Env encodes gp120 and gp41 proteins, which are displayed on the surface of the virion to 
facilitate binding and entry. Pol encodes the enzymes of HIV-1: reverse transcriptase, integrase, 
and protease. The regulatory protein Tat is necessary for viral gene transcription, and Rev is 
involved in the export of viral RNA from the nucleus to the cytoplasm for translation. The 
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accessory proteins of HIV-1 are multifunctional and modify the individual cell environment  to 
ensure viral replication, release and transmission [25] (Table 2).  
Table 2: Role of HIV-1 Accessory Proteins in Viral Pathogenesis. 
Function Protein Cellular Target 
Infection of Specific Cell Types Vpr Macrophages, resting T cells 
Inhibition of Cytoplasmic Defenses Vif APOBEC3 RNA editing 
Modulation of Antiviral Activities 
 at the Cell Surface 
Vpu Tetherin 
Proteasome-mediated Degradation Vif, Vpu, Vpr Cullin ubiquitin ligases 
Down-modulation of Host  
Cell Surface Molecules 
Nef CD4, T cell receptor, MHC class I 
Vpu CD4 
Modulation of the Intracellular 
Environment 
Vpr 
Cell cycle arrest, Apoptosis, 
Transcriptional regulation 
 
The life cycle of HIV-1 is divided into distinct stages (Figure 2). The virus binds to cell surface 
molecules and fuses with the host cell membrane. In the cytoplasm, uncoating of the viral RNA 
occurs, and the viral RNA is reverse transcribed into DNA. 
 
Figure 2: The replication cycle of HIV-1. HIV-1 enters the cell and reverse transcription occurs in the cytoplasm. 
Viral DNA integrates with cellular DNA, leading to the production of viral proteins which assemble at the cellular 
membrane. The virus matures and is released into the extracellular environment. 
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The pre-integration complex (PIC) forms and enters the nucleus of the cell. Viral DNA is 
integrated into the host cell's DNA, and transcription of viral RNAs occurs. Viral RNAs are 
translated, processed into individual proteins, and assembled in the cytoplasm. At the plasma 
membrane, the viral particle matures and is released into the extracellular environment.  
 
HIV-1 infects cells of the immune system, simultaneously hampering a cell's ability to 
effectively combat the infection and taking advantage of the immune synapse to spread to 
adjacent cells. The initial target cells of HIV-1 infection include macrophages, dendritic cells, 
and CD4+ T lymphocytes [26].  
2.2 DRUG TARGETS IN HIV INFECTION 
2.2.1 Approved Therapeutics 
In 1987, the reverse transcriptase inhibitor AZT was approved as the first therapy for HIV/AIDS 
[27]. This drug, and others that have followed it, is a nucleoside-analog reverse transcriptase 
inhibitor (NRTI). NRTIs compete with regular nucleotides for incorporation into the nascent 
DNA strand during reverse transcription and prevent the production of full-length viral DNA 
[28]. There is another class of reverse transcriptase inhibitors on the market: non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). NNRTIs bind directly to reverse transcriptase and 
cause a conformational change in the enzyme that disrupts the active site and prevents it from 
synthesizing new viral DNA [29]. 
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The first protease inhibitor was approved in 1995. Protease inhibitors prevent the cleavage of 
viral polyproteins into individual proteins and enzymes. Most of the inhibitors on the market are 
competitive inhibitors that mimic the shape of the natural substrate of protease [30]. Widespread 
resistance to current protease inhibitors has been seen in patients, and resistance mutations have 
been identified in both the protease enzyme and in the Gag polyprotein substrate [31]. 
 
The first integrase (IN) inhibitor was approved in 2007, and it remains the only IN inhibitor on 
the market. It inhibits the strand transfer function of integrase by binding to the enzyme-DNA 
complex and trapping it in an intermediate state so that the proviral DNA cannot be inserted into 
the host cell genome [32]. 
 
At the cell surface, therapeutics are available that target HIV-1 entry and fusion. Fusion 
inhibitors target the tethering of viral envelope to host cell membrane by gp41. There are 
multiple targets in the entry process, including CD4, CXCR4 and CCR5. Of these targets, only 
one has made it to market: a co-receptor antagonist to the chemokine receptor CCR5. 
Antagonists to the CXCR4 receptor are in clinical trials, as are monoclonal antibodies against the 
CD4 receptor [33]. 
2.2.2 Novel Work on Existing Drug Classes 
Additional inhibitors of reverse transcriptase (RT) have been identified in vitro and one has 
reached the clinical trial phase. KP-1212 uses the high mutation rate of the HIV genome against 
itself. It is a nucleoside that does not induce chain termination but rather induces viral 
mutagenesis with the goal of crossing the threshold for error capacity and ablating the viral 
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population as a whole [34]. Other groups have focused on inhibiting the RNaseH domain of RT 
or destabilizing the dimer needed to form the active RT enzyme [35, 36]. 
 
Novel strategies for targeting the protease enzyme include non-competitive inhibitors that bind to 
the flap of the enzyme, competitive inhibitors that fit closely within the substrate envelope region 
of protease, or small molecules that disrupt the dimerization of the enzyme [37-39]. Novel 
strategies for targeting the integrase enzyme include targeting the viral DNA binding step, 
inhibiting interaction with the cellular chromatin-tethering protein LEDGF, disrupting the 
dimerization and/or tetramerization properties of integrase, and disrupting the interaction with 
the viral cofactor Rev [40-43]. Novel strategies that target entry include the inhibition of gp160 
cleavage in infected cells [44]. 
2.2.3 Novel Targets 
Novel targets for antiretroviral therapies are being sought throughout the viral life cycle (Table 
3). Inhibitors of the late stages of viral replication (assembly, maturation and release) have 
generated particular interest, and the maturation inhibitor bevirimat has entered clinical trials [45, 
46]. Inhibitors of regulatory proteins and accessory proteins are also the subject of significant 
research. In addition to the targets in Table 3, which all have an effect on a single stage in the 
viral life cycle, inhibitors that target complex interactions in the host cell are also under 
development. The interaction of the accessory protein Nef with cellular kinase Hck has been 
found to be necessary for productive viral replication and thus is under scrutiny [47]. Vpr-
mediated apoptosis and cell cycle arrest have also been targeted [48, 49]. 
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Table 3: Novel Molecular Targets for Antiretroviral Therapy. 
Viral Protein Viral Replication Step Molecular Target/Mechanism Reference 
Tat Transcription Tat-TAR interaction [50] 
Rev Translation Rev nuclear export [51] 
Gag Release Gag-TSG101 interaction [52] 
Gag Maturation Gag processing cascade [46] 
Capsid Assembly Capsid oligomerization [53] 
Nucleocapsid 
Assembly 
Reverse Transcription 
Ejection of catalytic zinc 
molecule 
[54] 
Vpu Release Vpu-tetherin interaction [55] 
Vif Reverse Transcription Vif-APOBEC interaction [56] 
 
Other HIV-1 targeting strategies focus on more global targets. Latent reservoirs are a source of 
considerable interest because they prevent anti-retroviral therapy from curing patients of the 
disease. The main latent reservoir of HIV-1 is thought to be resting CD4+ T cells. Agents aimed 
at both non-specific and selective activation of HIV-infected CD4+ T cells have been identified 
[57, 58]. Other therapeutic strategies, known as virostatics, are aimed at reducing the level of 
chronic immune activation [21].  
 
The avenues that are being explored for HIV-1 therapeutics have widened considerably beyond 
the enzyme and cell surface molecules based treatments currently available. In particular, 
protein-protein interactions and dimerization have become feasible drug targets. With this new 
line of research has come a wave of research in therapies targeted at regulatory and accessory 
proteins. 
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2.3 PROTEIN-PROTEIN INTERACTIONS 
Protein-protein interactions (PPI) play critical roles in most cellular processes. Signal 
transduction cascades, membrane-bound receptor signaling, and ion channel formation are 
mediated by protein-protein interactions, and at its most basic level the antigen-antibody 
interaction is also considered a type of PPI [59]. Many viral proteins and enzymes require 
dimerization to become active, and the case of HIV-1 is no exception. Reverse transcriptase is a 
heterodimer, and protease is a homodimer composed of two identical subunits [36, 39]. The 
active site of integrase is present at the dimerization interface, and it is present as a dimer in the 
cytoplasm and a tetramer in the nucleus [42]. Similarly, HIV-1 Tat, Rev, Vif, Nef, and Vpr have 
also been found to dimerize in vivo [60-64].  
2.3.1 Structural Features 
Protein-protein interactions share several key structural features that can be used to determine 
their likely binding sites. Most protein interfaces are a result of higher level structural 
organization of a protein, not the sequence of its amino acids [59]. As a result, knowing a 
protein's molecular and/or crystal structure is often necessary for drug development. A potential 
dimer interface can be identified as a hydrophobic patch on the surface of a protein [65]. Protein 
interfaces, once thought to be large and flat, are actually composed of binding hot spots that 
involve relatively few amino acids [66].  
 
Knowing these hot spots can aid in rational and structure-based design of inhibitors (Figure 3). 
The rest of the interface is composed of anchor residues and residues with high flexibility to 
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accommodate the binding of ligands [67]. The knowledge of the structure of a protein and its 
interaction partner is beneficial in drug development. 
 
Figure 3: Example hot spot distribution on a protein-protein interface. The protein interface of the IL-2 
interleukin receptor is shown (A) in the absence of ligand and (B) bound to IL-2. Hot spot resides are shown in dark 
blue and adjacent interface residues are shown in light blue. Modified from [65]. 
 
2.3.2 Methods to Detect Dimerization 
Without an easily measured endpoint like that of an enzyme, protein-protein interactions had 
been ignored by the drug development community. The emergence of assays that detect 
interactions has changed that. Bait and prey methodologies such as the yeast two-hybrid system 
are a useful tool to ascertain the binding ability of two proteins; however, the yeast two hybrid 
system was limited in its ability to detect certain types of PPI. Advances have been made to 
allow not only the screening of cytoplasmic and membrane-bound proteins, but also to develop a 
mammalian two hybrid equivalent [68]. Additional advances in bait and prey systems have 
resulted in a variety of protein complementation systems, in which a molecule is split into two 
pieces and regains its functionality when the molecules are brought into close proximity by 
protein-protein interaction or dimerization [69]. 
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Fluorescence-based systems are a common detection system for dimerization due to the close 
proximity of the two proteins. Dimerization can be detected as either a quenching or release of 
fluorescence, depending on the bait and prey combinations. For cell-based assays, flow 
cytometry or automated fluorescence microscopy is used to measure a change in fluorescence 
intensity. FRET-based assays use a dual fluorophore system in which the emission of 
fluorescence from the first molecule excites the second, and the intensity of the fluorescence at 
the second emission wavelength is measured [70]. High throughput screening uses soluble 
proteins in vitro to assess binding through changes in fluorescence [71]. 
2.3.3 Targeting Dimerization 
Many strategies have been used to design molecules that target protein-protein interactions. 
Structure-based and rational design use co-crystallization of multiple ligands and/or fragments of 
known interacting proteins to determine the structure of the interface when a molecule is bound 
and creates a pharmacophore that shows ideal points of contact [41]. The consensus 
pharmacophore is used to electronically screen for small molecules that match these points of 
contact, and the results of this search are tested experimentally [72]. In fragment-based design, 
the initial hits are normally weak and techniques to increase the binding affinity of a fragment hit 
have been developed [73]. 
 
There are ways to improve the strength of PPI inhibitors beyond the synthesis of structural 
analogs. A fragment with weak or moderate binding affinity can benefit from the addition of a 
group with weak chemical reactivity designed to create a covalent bond with the protein target. 
The formation of covalent bonds is, as a general rule, avoided in drug development due to the 
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potential for non-specific interactions; however, the use of a weakly reactive group decreases the 
likelihood of these non-specific interactions [74]. This has been used to great effect in the 
treatment of prostate hyperplasia with the small molecule finasteride [75]. 
2.4 THE VIRAL PROTEIN R (VPR) 
The accessory protein Vpr is a multifunctional protein that plays a role in many aspects of HIV-1 
pathogenesis. Vpr arrests the cell cycle at the G2/M phase and induces apoptosis in bystander 
cells [76, 77]. It is also involved in immune suppression and neuropathogenesis [78-81]. Vpr is 
packaged into the virion, and it plays a role in the early stages of infection through 
transactivation of viral transcription and transport of the pre-integration complex into the nucleus 
[82-86]. Vpr has also been shown to facilitate the infection of macrophages and non-dividing 
cells [87, 88]. 
2.4.1 Vpr Structure 
Vpr is a protein composed of 96 amino acids with a molecular weight of approximately 14kDa.  
It has three alpha helices that form a hydrophobic core. Vpr associates into dimers, trimers and 
higher order oligomers in a concentration-dependent manner, and all three helices have been 
implicated in oligomerization [82, 89-91].  
 
Deficiencies in dimerization have been shown to affect cellular localization and to prevent 
incorporation into the viral particle [82, 92]. Vpr-deficient virus particles are less effective at 
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infecting macrophages, which are one of the primary targets of HIV-1 infection [93]. Without 
incorporation into the viral particle, Vpr cannot assist in early infection through transactivation 
of the LTR, nuclear import of the pre-integration complex, or modulation of the viral mutation 
rate via association of Ung2 [88]. Intentional inhibition of Vpr dimerization may have 
therapeutic benefits. 
 
No crystal structure of Vpr is available due to the formation of insoluble protein aggregates at the 
concentrations required to crystallize proteins; however NMR data has been obtained for the full 
length protein in two different solvents [90]. Our laboratory has used this NMR data to generate 
models of the dimerized form of Vpr (Figure 4). 
 
Figure 4: Proposed dimer orientations for Vpr. Two possible configurations for the dimerization of Vpr were 
generated from full length NMR structures using computational modeling. (A) Proposed parallel configuration of 
the dimer. (B) Proposed antiparallel configuration. [82] 
 
Mutagenesis studies have shown that over 10 point mutations can result in dimerization deficient 
Vpr [91]. These mutations are spread over all three helices, but the majority are thought to be 
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involved in the stability of the hydrophobic core and not available for a protein-protein interface. 
The residues positioned to allow for inter-molecular interactions are Q44 from helix 2, and L67 
from helix 3.  
2.4.2 Known Inhibitors of Vpr 
HIV-1 Vpr is a multifunctional protein. Several groups have discovered inhibitors of selected 
Vpr functions. The majority of the studies focused on inhibition of Vpr-mediated cell death and 
growth inhibition due to cell cycle arrest. Eight inhibitors have been found, and they are 
summarized in Table 4. 
Table 4: Known Inhibitors of Vpr Functions 
Inhibitor 
Discovery 
Method Functions Inhibited Reference 
Pentoxifylline Yeast screen Cell cycle arrest, apoptosis [94] 
Hexameric peptides with 
di-tryptophan motif 
Yeast screen Cell cycle arrest, apoptosis 
[95] 
Fumagillin Yeast screen Cell cycle arrest, apoptosis [49] 
Damnacanthal VLP-infection Apoptosis [48] 
Mifepristone Co-transfection LTR transactivation [96] 
Hematoxylin In-vitro binding 
Nuclear transport of PIC 
through importin-alpha 
[17] 
SIP-1 In-vitro binding Macrophage infection [97] 
Vipirinin Yeast screen Cell cycle arrest  [98] 
 
Screening for over half the published inhibitors occurred in yeast systems. The mammalian 
systems used transfection and transduction to introduce Vpr to cells in an effort to reduce cell 
death. Newer assays have incorporated protein arrays on slides or adsorbed to an ELISA plate. 
Three inhibitors have been found that inhibit multiple functions of Vpr. An apoptosis-specific 
inhibitor and a cell cycle arrest specific inhibitor have also been discovered. Less common 
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targets such as nuclear transport and transactivation have also been targeted; however, no screen 
has been undertaken to interfere with the oligomerization properties of Vpr. 
 
Here, I propose to develop a cell-based screen to target HIV-1 protein oligomerization, using the 
oligomerization of Vpr as a “proof-of-concept”. After optimizing and validating this screening 
system, I will apply it to two libraries with the goal of identifying a compound that inhibits the 
dimerization properties of Vpr. Whether the libraries yield an inhibitor or not, the validation of 
this screen for oligomerization is easily adaptable to additional dimeric protein and can have a 
wide range of use in the study and screening of protein-protein interactions. 
  17 
3.0  THESIS AIMS 
The success of HAART has turned HIV-1 infection into a chronic disease.  However, existing 
antiretroviral therapies have serious side effects, and viral escape mutants can develop against 
entire classes of HIV drugs. The necessity of developing new antiviral compounds to treat HIV-1 
infection has led to the investigation of virus-encoded proteins including the accessory protein 
Vpr, which has multiple functions in HIV-1 pathogenesis.  
 
Macrophages are an important target for HIV-1, both in initial infection and as reservoirs of 
virus. The infection of macrophages requires the incorporation of Vpr into the viral particle so 
that it may assist with translocation of the pre-integration complex into the nucleus. Vpr-
deficient virions have been shown to produce a less robust infection of macrophages. It has been 
determined that one of the mechanisms needed for Vpr incorporation into the viral particle is 
Vpr-Vpr oligomerization. In the absence of oligomerization, Vpr molecules are unable to interact 
with Gag and be packaged into virions. 
 
The three major aims of this thesis included first characterizing a fluorescence complementation 
system for detection of oligomerization.  Secondly, we wanted to determine whether the 
sensitivity existed to make quantitative assessments about oligomerization. Thirdly, we wanted 
to view the effect of two small libraries on Vpr-Vpr oligomerization.  
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AIM #1: To characterize the bimolecular fluorescence complementation system for 
detection of oligomerization 
A) To develop a reproducible co-transfection system for bimolecular fluorescence 
complementation (BiFC). 
B) To determine localization of the BiFC signal. 
C) To determine kinetics of protein expression and BiFC detection. 
D) To assess the level of non-specific BiFC signal. 
 
AIM #2: To quantify a decrease in fluorescence using a competition assay 
A) To develop a competition assay using untagged Vpr. 
B) To quantify fluorescence through flow cytometry. 
C) To quantify fluorescence through immunofluorescence. 
 
AIM #3: To assess libraries for an effect on Vpr oligomerization 
A) To determine optimum concentrations of solvent and libraries. 
B) To validate a high content imaging screen. 
C) To assess a library of Vpr peptides. 
D) To assess a library of small molecule leucine rotamers. 
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4.0  MATERIALS AND METHODS 
4.1 CELL LINES 
HeLa and HEK293T cell lines were grown in DMEM (Gibco) supplemented with 10% FBS 
(HyClone), 1% Penicillin-Streptomycin (Invitrogen), and 1% L-glutamine (Invitrogen) [D-10]. 
HeLa and HEK293T cells were grown in 5% CO2 at 37°C. HeLa cells were obtained through the 
NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, contributed by 
Dr. Richard Axel. HEK293T cells were given by Dr. Michelle Calos, Stanford University, CA. 
4.2 PLASMIDS 
All plasmids were generated by propagation in DH5alpha bacterial cells, and DNA was extracted 
using the Qiagen MaxiPrep kit (QIAGEN). Mammalian expression plasmids for HIV-1 Vpr 
containing either an HA-tag at the N-terminus or a Flag-tag at the C-terminus were used as 
“untagged” Vpr in the competition assays. 
 
The Venus N and Venus C fusion constructs used in this paper were generated by Dr. Jay 
Venkatachari as described in [82]. Briefly, sequences encoding the amino (residues 1-173; VN) 
or carboxyl (residues 155-238; VC) fragments of Venus fluorescence protein were fused to the N 
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terminus of HIV-1 Vpr via a six alanine linker sequence and an HA-tag for detection (Figure 5). 
Venus constructs of wildtype Vpr, Q44, and A30L were used.  
 
Figure 5: Venus plasmid constructs. 
4.3 TRANSFECTION METHODS 
4.3.1 Calcium Phosphate 
The calcium phosphate method was used on HEK293T and HeLa cell lines. Cells were plated to 
reach 70% confluence. Three hours prior to cell transfection, cell media was replaced with fresh 
D-10 media. The transfection was conducted by adding DNA (450µL) to water (450µL) to 2.5M 
CaCl2 (50µL). To the DNA-water-CaCl2 mix, 50mM BES (BES, 250mM NaCl, 0.5mM 
Na2HPO4) (500µL) was added and the mixture was incubated at room temperature for 30 
minutes. After incubation, the mixture was added dropwise to cells. Within 6-12 hours, the 
media on the cells was removed, the cells were washed once with PBS to remove all precipitate 
and excess DNA, and fresh D-10 was added. 
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4.3.2 Lipofectamine Transfection 
 Lipofectamine 2000 transfection was used on HeLa cells according to manufacturer's protocol. 
Briefly, cells were plated and grown to 70% confluence. 30 minutes prior to transfection, cells 
were given fresh D-10 media. Plasmid DNA was mixed with DMEM and Lipofectamine 2000 
(Invitrogen). The DNA-Lipofectamine complex was incubated at room temperature for 20 
minutes then added dropwise to cells. After 5 hours, media was removed, cells were washed to 
remove any excess DNA or Lipofectamine, and fresh D-10 media was added.  
4.3.3 PolyJet Transfection 
PolyJet transfection was used on HEK293T and HeLa cells according to manufacturer's protocol. 
Briefly, cells were plated and grown to 75% confluence. 30 minutes prior to transfection, cell 
media was replaced with fresh D-10 media. The transfection was conducted by diluting plasmid 
DNA in DMEM, then adding PolyJet DNA Transfection Reagent (SignaGen) diluted in DMEM. 
The DNA-PolyJet complex was incubated for 15 minutes then added dropwise to cells. After 5-
24 hours, the DNA-PolyJet complex was removed and fresh D-10 media was added. 
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4.4 SMALL MOLECULE LIBRARIES 
4.4.1 Vpr Peptide Library 
A library of HIV-1 Consensus B VPR (15-mer) Peptides was obtained from the NIH AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. The library contains 
22 peptides, 15 amino acids in length, with 11 amino acid overlaps between sequential peptides. 
Peptides were reconstituted from lyophilized powder in solvents (H2O, PBS, or DMSO) 
according to the NIH-provided solubility table (Appendix 1).  
4.4.2 Leucine-based Small Molecule Library 
A library of 45 leucine rotamers was a generous gift from Dr. Alexander Dömling (University of 
Pittsburgh). The library was received as 10mM stocks dissolved in DMSO. 
4.5 IMMUNOFLUORESCENCE ANALYSIS AND IMAGING 
The antibodies used for immunofluorescence experiments are monoclonal anti-HA (Sigma; 
1:200) and monoclonal anti-Flag M2 (Sigma; 1:300). Transfected HeLa cells were grown on 
coverslips and fixed with 2% paraformaldehyde in PBS for 15 minutes. Coverslips were washed 
with PBS, treated with 0.1% Triton X-100 (Fisher Scientific) in PBS for 15 minutes, and washed 
again with PBS. Coverslips were blocked with PBS containing 2% bovine serum albumin (BSA; 
Sigma) for 45 minutes and incubated for 90 minutes at 37°C with primary antibodies as 
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described above, followed by additional washing with 0.5% BSA in PBS. Coverslips were 
incubated with Cy5-tagged secondary antibody (Jackson ImmunoResearch; 1:800) for 60 
minutes then washed with 0.5% BSA in PBS. Hoechst 33342 nuclear stain (Sigma) was applied 
for 2 minutes and coverslips were washed with PBS. Gelvatol mounting media was provided by 
the Center for Biological Imaging (CBI) to adhere coverslips to slides.  
 
Confocal multicolor images using the FITC, Cy5 and DAPI channels were recorded using an 
Olympus Fluoview 500 upright microscope at the Center for Biologic Imaging at the University 
of Pittsburgh School of Medicine. Spot intensity quantitation was performed using MetaMorph II 
software at the Center for Biologic Imaging. The images were thresholded to reduce background 
noise, and the nuclear region was selected in the FITC channel of an image. Region statistics 
were used to record the average intensity of the FITC signal in the nucleus and its standard 
deviation. 
4.6 WESTERN BLOT 
Cells were lysed using lysis buffer containing 50mM Tris (pH 7.5), 150mM NaCl, 1% Triton X-
100, 1mM sodium orthovanadate, 10mM sodium fluoride, 1.0mM phenylmethylsulfonyl 
fluoride, 0.05% deoxycholate, 10% sodium dodecyl sulfate, aprotinin (0.07 trypsin inhibitor 
unit/ml), and the protease inhibitors leupeptin, chymostatin, and pepstatin (1μg/ml; Sigma) and 
protein levels were quantitated with the Pierce BCA Protein Assay kit (Thermo Scientific). 
Protein (30µg) was run on a 12% SDS-PAGE gel. Proteins were transferred to Immobilon PVDF 
membrane (Millipore) and the membrane was blocked in 2% BSA for 1 hour. Membranes were 
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incubated in primary antibody overnight at 4°C and washed in PBS containing 0.1% Tween-20 
(PBS-T; Fisher Scientific). Secondary antibody was applied for one hour at room temperature. 
Membranes were exposed to Pierce SuperSignal West Pico chemiluminescent substrate (Thermo 
Scientific) then developed. 
4.7 FLOW CYTOMETRY 
Twenty hours post-transfection, HeLa cells were trypsinized and pelleted. Cells were fixed in 4% 
paraformaldehyde for 10 minutes, then pelleted and resuspended in 5% fetal bovine serum in 
PBS. Data was collected using a BD FACSCanto flow cytometer (Becton Dickenson) and 
FACSDiva software (Becton Dickenson). Cells were gated according to the following 
parameters. Forward and side scatter were used to identify the live population, and 20,000 live 
events were recorded. The FITC positive gate was set based on cells "mock" transfected with 
empty pcDNA 3.1 vector. The gate was positioned to contain no more than 1% of mock-
transfected cells. The mean fluorescence intensity was obtained from this gate. Data was 
analyzed using Flow Jo software. 
4.8 COMPETITION ASSAYS 
Cells were grown to 75% confluence in 6 well plates. Cells were transfected with a total of 2µg 
of plasmid DNA according to PolyJet protocol. Equal amounts of VN-Vprwt and VC-Vprwt were 
added to each well, and the total quantity of VN- and VC- Vpr was referred to as "Venus Vpr." 
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Ratios were created to represent the amount of Venus-Vpr to untagged Vpr in each transfection. 
The ratios ranged from 1:0 to 1:10. A negative control of 0:1 was used, containing the same 
quantity (in ng) of untagged Vpr as the quantity of Venus-Vpr in the corresponding 1:0 control. 
Twenty hours post-transfection, cells were collected for Western blot and flow cytometry 
analysis. 
4.9 SCREENING ASSAYS 
Cells were grown to 75% confluence in a 10cm2 plate and transfected with equal quantities of 
VN-Vpr and VC-Vpr. Five hours post-transfection, cells were washed with PBS, trypsinized, and 
replated into a 96 well plate at a density of 9,000 cells/well in 200µL of D-10. Wells were treated 
in triplicate with 2µL of a compound. Plates were incubated at 37°C for a total of 24 hours post-
transfection. 
4.9.1 Cytotoxicity 
To determine the percentage of cellular toxicity in vitro of each compound, the MTT 
Tetrazolium assay was performed. Twenty-four hours post-transfection, 20µL of 5mg/mL 
thiazolyl blue tetrazolium bromide (Sigma) was added to each well. Four hours later, cell media 
was removed and replaced with 100µL DMSO (Sigma). 
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4.9.2 Flow cytometry 
Twenty-four hours post-transfection, cells were washed and trypsinized in the 96 well plate. 
Cells were spun down, resuspended in 4% paraformaldehyde for 15 minutes. Cells were spun 
down and resuspended in 5% FBS in PBS. The plate was run using the plate reader functionality 
of a BD LSRII flow cytometer (Becton Dickenson). Data was analyzed using Flow Jo software. 
4.9.3 High Content Imaging 
Cells were washed twice with PBS and fixed with 4% paraformaldehyde for 15 minutes. Cells 
were washed in PBS and stained with Hoechst nuclear stain (Sigma) for 1 minute. Cells were 
stored in 100µL PBS, and plates were sealed with MicroAmp sealing film (Applied Biosystems). 
 
Plates were analyzed by automated fluorescence microscopy using the ArrayScan VTI HCS 
Reader imaging cytometer (Thermo Scientific Cellomics). Data was collected in the FITC, 
TRITC and DAPI channels. Data was analyzed using the BioApplications platform (Thermo 
Scientific). Background fluorescence was eliminated through comparison of FITC and TRITC 
channel intensities. Using this filtered set, cells with a small nuclear area were excluded to 
eliminate the dead/dying population. The remaining cells were analyzed for mean nuclear FITC 
intensity. Data collection and analysis was performed by the Cytometry facility at the University 
of Pittsburgh Cancer Institute with assistance from William Buchser. 
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5.0  RESULTS 
5.1 AIM #1: TO CHARACTERIZE THE BIMOLECULAR FLUORESCENCE 
COMPLEMENTATION SYSTEM FOR DETECTION OF OLIGOMERIZATION 
5.1.1 Bimolecular Fluorescence Complementation 
To detect Vpr-Vpr dimerization/oligomerization, we have utilized a variation on the bait and 
prey system known as protein fragment complementation. Protein fragment complementation 
uses two fragments of a single protein that is reconstituted through the interaction of its two 
halves [99]. Many protein fragment complementation systems exist, such as those for ubiquitin, 
dihydrofolate reductase, and split luciferase [100-102]. Bimolecular fluorescence 
complementation (BiFC) uses a split fluorescent protein fused to the protein(s) of interest to 
detect their interaction (Figure 6).  
 
Figure 6: Schematic representation of BiFC system. Restoration of fluorescence occurs through oligomerization 
of fusion proteins. 
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We are using the YFP-derived Venus fluorophore, which is divided into an N terminal (amino 
acids 1-173) and C terminal fragment (amino acids 155-238). For simplicity, these fragments 
will be referred to as VN and VC for the duration of this paper.  
5.1.2 BiFC Assay Parameters 
From the start of assay development, the ultimate goal was to design a high content screen that 
would be read in a 96 well plate. Two possible transfection strategies were considered: seeding 
cells directly into a 96 well plate and transfecting each well individually, or seeding cells into a 
larger plate for transfection then moving them to a 96 well plate. We chose the latter because 
performing 96 individual transfections would introduce added well-to-well variability in 
transfection efficiency that could skew the interpretation of results. One disadvantage of this 
method is the need to replate the cells because trypsinization is stressful for cells. This was taken 
into account when choosing a cell line; each line was tested under these experimental conditions 
to determine whether it could handle the added stress of replating. 
 
BiFC is a fluorescence reporter assay which is used both quantitatively via flow cytometry and 
qualitatively via immunofluorescence microscopy [69]. Smaller, suspension cells are preferred 
for flow cytometry, and larger cells are more suited for image-based analysis. Though the final 
form of the assay is a high content screen, preliminary work was performed using flow 
cytometry. Adherent cells that are screened with flow cytometry must be able to survive 
trypsinization three times in 48 hours, so the cell line needed to be hardy and the transfection 
agent needed to be non-cytotoxic. 
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5.1.2.1 Selection of Cell Line 
 
We began with HEK293T cells due to their capacity for high protein expression, but HEK293T 
cells are not ideal for the multiple washes necessary in preparation for flow cytometry. Despite 
efforts to wash cells gently, greater than 40% of cells were lost in the preparation process. Of the 
cells that remained, only 20-30% were positive for fluorescence. In addition to the cell loss, 
significant morphological changes in the forward and side scatter were observed between the 
non-transfected and transfected cells, most likely due to cellular stress from the replating (Figure 
7). These factors eliminated HEK293T as a model cell line. We next tried the non-adherent 
Jurkat cell line but were unable to transfect the cells by calcium phosphate, Lipofectamine 2000, 
or nucleofection methods. 
 
Figure 7: Morphological changes after transfection protocol. Transfected cells were replated 6 hours post-
transfection and collected for flow cytometry analysis at 24 hours. Un-transfected cells were collected for flow 
directly from a culture flask 
 
Our third choice for cell line was the HeLa cell line. This assay is ultimately designed to be an 
imaging-based screen, for which large adherent cells, like those of the HeLa or COS-7 lines, are 
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ideal. Since HeLa cells are more tightly adherent than HEK293T cells, they tolerate the washings 
in preparation for flow cytometry better. After the replating procedure, HeLa cells did not show 
morphological changes like those seen in HEK293T cells (Fig. 7). We tested two different HeLa 
cell lines (HeLa and HeLa T4+) and chose from these based on their responses to transfection 
reagents. 
5.1.2.2 Selection of Transfection Reagent 
 
In order to choose the optimum transfection reagent for our cell lines, we looked for two 
qualities: high transfection efficiency and low cytotoxicity. We ranked low cytotoxicity as more 
important than high transfection efficiency due to the added stress our assay will create due to 
the replating step. HEK293T cells were transfected according to a calcium phosphate protocol, 
but this protocol is not used in our laboratory for HeLa cells. HeLa cells were transfected first 
using Lipofectamine. After a co-transfection of the BiFC plasmid set, this system transfected 
15% of both HeLa and HeLa T4+ cells. Cytotoxicity was measured as the percentage of rounded 
or floating cells. Forty percent of HeLa cells and 55% of HeLa T4+ cells exhibited cytotoxicity 
(Figure 8). 
 
PolyJet DNA transfection reagent was tested on both HeLa cell lines as well as in HEK293T 
cells. The PolyJet system produced greater than 50% fluorescence from co-transfection in all 
three cell lines. HeLa T4+ cells showed the highest co-transfection efficiency at 65%, and HeLa 
cells were slightly lower at 60%. PolyJet-induced cytotoxicity was lower than that of the calcium 
phosphate and Lipofectamine systems in all cell lines tested. The cytotoxicity was 5% in the 
HeLa cell line and 15% in the HeLa T4+ cell line.  
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Figure 8: Efficiency and cytotoxicity of transfection in multiple cell lines. Cell lines were transfected according 
to calcium phosphate, lipofectamine or PolyJet protocol. 38 hours post-transfection, cells were observed under a 
fluorescence microscope for (A) percentage of fluorescent cells and (B) cytotoxicity as measured by morphological 
change and floating cells. 
 
HEK293T cells were eliminated as a potential cell line due to toxicity from the transfection 
process, so cytotoxicity was seen as the most important criterion. Therefore, while HeLa T4+ 
cells had higher transfection efficiency, its cytotoxicity led us to chose the HeLa cell line for the 
remainder of our experiments.  
5.1.3 Localization of BiFC Signal 
High content analysis is imaging-based, which gives it the capability to determine the 
localization of proteins. A nuclear stain is used to obtain a cell count, and the analysis software is 
capable of quantitating the nuclear and cytoplasmic fluorescence independently. In order to 
determine which analysis is more relevant to the Venus fragment-fused proteins, we looked at 
the localization of VN-Vpr and VC-Vpr in HeLa cells. Vpr is known to localize to the nuclear 
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membrane; however, larger fusions have been shown to exclude Vpr from the nucleus. Twenty -
four hours post-transfection, cells were fixed and stained with antibody to the HA tag in the 
linker region in order to identify transfected cells (Figure 9).  
 
Figure 9: Localization of BiFC signal. Cells were grown on coverslips, transfected and fixed 24 hours post-
transfection. Cells were stained with α-HA primary, Cy5-conjugated secondary and DAPI, and viewed under a 
confocal microscope at 60X magnification. 
 
Both Vpr fusion proteins localize in and around the nucleus. VN-Vpr is found almost exclusively 
in the nucleus, whereas VC-Vpr has more diffuse localization throughout the cell. The 
transfections of VN- and VC- alone gave no BiFC signal in the FITC channel. The co-
transfection exhibited robust BiFC signal that co-localizes with the HA staining. Since the BiFC 
signal is concentrated in the nucleus, we focused on the intensity of BiFC signal in the nucleus in 
the following aims 2 and 3. 
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5.1.4 Kinetics of Protein Expression 
The reconstitution of the Venus fluorophore is irreversible. Therefore, in order to see an effect 
from an exogenously added peptide or small molecule, it is necessary to treat cells before the 
expressed proteins have a chance to interact. To determine when the fusion proteins are 
expressed in the cell, we co-transfected cells with equal amounts of VN-Vpr and VC-Vpr 
plasmid and collected cells at various times post-transfection. 
 
Figure 10: Protein expression in co-transfected HeLa cells. Cells were co-transfected with equal amounts VN-
Vpr and VC-Vpr. At the indicated times post-transfection, cells were collected for further analysis. (A) Cells were 
lysed and analyzed via Western blot using anti-HA antibody. (B) Cells were fixed and analyzed with flow 
cytometry. 
 
Protein expression can be detected as early as six hours post-transfection in HeLa cells, and by 
twelve hours the protein levels saturate the detection levels of the Western blot (Fig 11A). BiFC 
signal remains under 10% until twelve hours post-transfection (Fig 11B). The delay between 
protein expression and BiFC fluorescence detection is likely due to the maturation time needed 
for the reconstitution of the Venus molecule [103]. Since protein expression can be detected as 
early as six hours post-transfection, we determined that exogenous compounds should be added 
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to cells six hours post-transfection. In terms of assay set-up, we chose to trypsinize our cells and 
begin the replating process five hours post-transfection. 
5.1.5 Specificity of the BiFC Interaction 
Vpr-Vpr oligomerization occurs via random interaction between two Vpr molecules. In a 
transient transfection system, proteins are often overexpressed, increasing the likelihood of 
interaction inside the cell. The strong CMV promoters used in our Venus constructs are no 
exception. The restoration of the Venus fluorescent molecule occurs at distances under 100nm. 
Because of the increased protein levels in the cell and the tendency of Vpr to oligomerize, there 
is a risk of non-specific restoration of Venus fluorescence inherent in the BiFC system. To assess 
the frequency and strength of non-specific interaction, we used Venus plasmid sets with two Vpr 
mutants known to be dimerization deficient: VprA30L and Vpr QΔ44 [82]. We transfected cells with 
combinations of wildtype and mutant VN- and VC- Vpr and analyzed the percentage and 
intensity of cells that were positive by flow cytometry (Figure 11).  
 
Forty-eight percent of the cells transfected with wildtype VN- and VC-Vpr were positive for 
BiFC signal. When the transfected VN- and VC- were both dimerization deficient, 
approximately 4% of cells were positive for BiFC signal. When transfected with wildtype VN-
Vpr and a dimerization mutant VC-Vpr, the QΔ44 mutant showed a similar percentage of 
positive cells and the A30L mutant showed 10.52% positive cells. 
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Figure 11: BiFC signal in dimerization-deficient Vpr mutants by flow cytometry. Cells were transfected with 
VN- and VC- plasmids and collected for flow cytometry analysis 24 hours post-transfection. A) Histograms 
showing the intensity of FITC signal. (Black line = control cells; shaded = mutant) B) The mean fluorescence 
intensities from each sample. 
 
Since there is a consistent population of BiFC-positive cells, it is important to consider the 
degree to which they are positive. In flow cytometry, a cell is excited with a laser and the total 
fluorescence intensity for that cell is measured. The histograms are comprised of the distribution 
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of individual cell fluorescence intensities. In the dimerization mutant samples, the histograms are 
widened and shifted slightly to the right. None of these samples shows the second (positive) peak 
that is apparent in the wildtype VN- and VC-Vpr histogram. To confirm this, we looked at the 
mean fluorescence intensity of the entire sample (Fig. 11B). The mean fluorescence intensities of 
the positive cells in the wildtype VN- and VC- transfection are ten times as high as those of the 
dimerization mutant pairings, and the mutants' intensity levels are equivalent to the "mock" non-
transfected cells.  
 
In HeLa cells, we have found that the BiFC system produces non-specific interactions in 10-20% 
of cells, but the flow cytometry indicated that the interactions themselves are of low intensity, 
meaning they occur infrequently within a single cell. We assessed the intensity of BiFC signal in 
context of a high content imaging system (Figure 12). A total of 45 high content images for the 
VprA30L and VprQ∆44 mutants were analyzed for fluorescence in the FITC channel. No nuclear 
fluorescence can be observed in either mutant. In the VprA30L mutant, a few cells can be seen 
with low level cytoplasmic fluorescence; however, the fluorescence pattern is distinct from that 
of true BiFC interactions. In an imaging-based system, this level of background is all but 
undetectable.  
 
Figure 12: BiFC signal in dimerization deficient mutants by fluorescence microscopy. Cells were transfected 
with VN- and VC- plasmids for 5 hours, then moved into a 96 well plate. 24 hours post-transfection, cells were 
fixed, stained and imaged using high content analysis.  
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5.1.6 Summary of Aim #1 
The focus of Aim #1 was to characterize the bimolecular fluorescence complementation system 
for Vpr oligomerization. Optimal cell lines and transfection reagents were determined in order to 
conduct all the following assays. The kinetics of BiFC protein expression were explored in order 
to determine the time by which exogenous compounds must be added in screening experiments. 
The nuclear localization of individual Venus plasmids and BiFC signal was observed and will be 
the target of our high content analysis. Furthermore, dimerization deficient mutants were found 
to produce a consistent, low level BiFC signal that is similar in intensity to non-transfected cells. 
5.2 AIM #2: TO QUANTIFY A DECREASE IN FLUORESCENCE USING A 
COMPETITION ASSAY 
5.2.1 Competition Assay Theory 
In Aim #1 we showed that the BiFC system can detect Vpr oligomerization. However, in order to 
function as a screening tool, the BiFC system must be able to quantitatively detect changes in 
oligomerization levels. Ideally we would use an increasing concentration of a Vpr-specific 
dimerization inhibitor, but no such inhibitor has been identified. Without this inhibitor, we chose 
to take advantage of the bimolecular nature of the BiFC system in designing a proof-of-concept 
assay. 
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Figure 13: Schematic representation of the BiFC competition assay. Transfection of fusion-less Vpr along with 
the VN and VC plasmids increases the amount of non-fluorescent dimerization products. 
 
Vpr dimerizes regardless of which fusion protein is attached to it. In every BiFC co-transfected 
cell, three sets of dimers will be present: VN-Vpr + VC-Vpr, VN-Vpr + VN-Vpr, and VC-Vpr 
+VC-Vpr (Fig. 13A). Of these three sets, only the VN-VC dimers produce BiFC fluorescence. 
By expressing Vpr without an attached fusion protein, we double the total number of possible 
configurations dimerized Vpr can assume (Fig. 13B). By increasing the amount of untagged Vpr 
transfected into each cell, the percentage of dimers formed in the BiFC configuration is 
decreased. 
 
We devised ratios to represent the total input of Venus plasmids and untagged Vpr. The total 
input of Venus plasmids (referred to as "Venus-Vpr") was calculated as the sum of VN-Vpr and 
VC-Vpr DNA transfected per well. The untagged Vpr input was determined in relation to the 
amount of Venus-Vpr transfected in order to achieve a given ratio. As an example, a 1-to-4 ratio 
with a 200ng Venus-Vpr input would be co-transfected with 800ng of untagged Vpr. 
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One limiting factor of this approach was the maximum amount of DNA that could be tolerated 
by cells. According to the manufacturer's protocol for PolyJet transfection, a total of 1µg of 
plasmid DNA was recommended. Experimentally, we found that up to 2µg could be transfected 
without increasing cytotoxicity. However, even this amount of plasmid was found to be a 
limiting factor in achieving higher ratios of Venus-Vpr to untagged Vpr. A 1-to-10 ratio was the 
highest attempted. 
5.2.2 HA-Vpr as an untagged competitor 
We first attempted to use a construct of Vpr tagged at the N-terminus with an HA epitope 
(referred to as HA-Vpr) as our untagged competitor. We used a total of 2µg for each sample and 
adjusted the inputs of both Venus-Vpr and HA-Vpr to reflect the desired ratio (Table 5). 
 
Table 5: Transfection scheme with variable inputs of Venus-Vpr 
Ratio Venus-Vpr (µg) HA-Vpr (µg) 
1 : 0 2 -- 
1 : 1 1 1 
1 : 2.5 0.66 1.34 
1 : 5 0.4 1.6 
1 : 10 0.2 1.8 
0 : 1 -- 2 
 
Samples were transfected with the plasmid ratios described above and analyzed via flow 
cytometry 24 hours post-transfection. Both the percentage of BiFC positive cells and the mean 
fluorescence intensity of BiFC positive cells were assessed (Figure 14). 
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Figure 14: Variable Venus-Vpr input results in non-comparable protein expression levels. Cells were 
transfected with 2ug of plasmid comprising different ratios of Venus-Vpr to HA-Vpr. 24 hours post-transfection, 
cells were harvested and analyzed by flow cytometry. 
 
As the amount of HA-Vpr plasmid was increased, a steady decrease in the percentage of positive 
cells was observed. A decrease of approximately 10% was seen between each ratio, and at a 1:10 
ratio the amount of BiFC positive cells had decreased by 50%. A similar linear decrease was 
seen in the mean fluorescence intensity of BiFC positive cells.  
 
To verify these results, we looked at the protein expression levels in transfected cells by Western 
blot. The variable input of Venus plasmids resulted in different basal levels of tagged Vpr. 
Without a way to standardize the different levels, no conclusions can be drawn about the BiFC 
signal between these samples. Venus plasmid input must be held constant in order to compare 
the effect of increasing the untagged Vpr. 
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We next held the amount of Venus-Vpr constant at 400ng (200ng of VN-Vpr and 200ng of VC-
Vpr). Control pcDNA3.1 plasmid was added as needed so the total amount of plasmid 
transfected was 2μg (Table 6). 
 
Table 6: Transfection scheme with constant level of HA-Vpr. 
Ratio 
Venus-Vpr 
(μg) 
HA-Vpr  
(μg) 
pcDNA vector  
(μg) 
1 : 0 0.4 -- 1.6 
1 : 1 0.4 0.4 1.2 
1 : 2 0.4 0.8 0.8 
1 : 4 0.4 1.6 -- 
0 : 1 -- 0.4 1.6 
 
 
The new transfection scheme was assessed for protein expression by Western blot (Figure 15). 
The levels of Venus plasmids were equivalent in each of the sample lanes. However, the HA-Vpr 
expression was lower than that of VN-Vpr and VC-Vpr, even at four times the plasmid input. 
200ng of VN-Vpr and VC-Vpr plasmids produced levels of protein higher than 1.6μg of HA-
Vpr. The HA-Vpr plasmid was prepared fresh from a glycerol stock, subcloned, re-purified, and 
tested five times with similar results. Because of the low expression and 2μg limit for plasmid 
DNA input, we chose to switch to another construct for our untagged Vpr.  
 
Figure 15: HA-Vpr expression is suboptimal. Cells were transfected as described in Table 6 and ollected after 24 
hours for Western blot analysis using α-HA antibody. 
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5.2.3 Vpr-Flag as an untagged competitor 
Since the HA-Vpr plasmid was not capable of high expression, we switched to a construct of Vpr 
tagged at the C-terminus with a Flag epitope (Vpr-flag) as the untagged competitor. In addition, 
the amount of Venus-Vpr was decreased to 200ng (100ng of VN-Vpr and 100ng of VC-Vpr). 
Control pcDNA3.1 plasmid was added as needed so the total amount of plasmid transfected was 
2μg (Table 7). 
 
Table 7: Transfection scheme for Vpr-flag competition assay. 
Ratio 
Venus-Vpr 
(μg) 
Vpr-flag 
(μg) 
pcDNA vector 
(μg) 
1 : 0 0.2 -- 1.8 
1 : 1 0.2 0.2 1.6 
1 : 2 0.2 0.4 1.4 
1 : 4 0.2 0.8 1.0 
1 : 8 0.2 1.6 0.2 
0 : 1 -- 0.2 1.8 
 
 
As before, cells were transfected and observed 24 hours post-transfection. In sample wells with a 
high input of Vpr-flag plasmid, apoptosis/cell death was observed. Therefore, we reduced the  
end point to 18 hours post-transfection to avoid time-dependent toxicity. Cells were harvested for 
flow cytometry and analyzed for percentage of BiFC positive cells and mean fluorescence 
intensity of BiFC positive cells (Figure 16). The graphs in Figure 16 represent the averages over 
4 experiments. The values in each experiment have been normalized to the 1:0 sample, which 
was taken to be 1.  
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Figure 16: High concentrations of Vpr-flag decrease the mean fluorescence intensity. Cells were transfected as 
described in Table 3 and collected for flow cytometric analysis 18 hours post-transfection. Experiments were 
repeated (n=4) and the data from each were normalized to the 1:0 sample. (A) The percentage of BiFC positive cells 
and (B) the mean fluorescence intensity are plotted. 
 
Interestingly, both the mean fluorescence intensity (MFI) and percentage of positive cells 
increase when Vpr-flag is co-transfected along with the Venus-Vpr plasmids. The percentage of 
positive cells increases by 65%, and the MFI increases by 30%. After this initial increase, the 
percentage of BiFC positive cells remains constant, and the MFI decreases. These results are 
seen with a Venus-Vpr plasmid input of 400ng as well (data not shown). This may be due to 
higher order oligomerization as opposed to dimerization. 
 
The mean fluorescence intensity (MFI) shows an initial spike with the co-transfection of 
untagged Vpr, but decreases steadily afterwards. The level is reduced to that of Venus-Vpr alone 
at a ratio of 1-to-4, and is decreased to 70% of the Venus-Vpr alone level at the 1-to-8 ratio.  
Visually, these decreases can be seen in the histograms for BiFC fluorescence (Figure 17). 
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Figure 17: Co-transfection of Vpr-flag produces a re-distribution in the histogram shape. Cells were 
transfected as described in Table 7 and collected for flow cytometric analysis 18 hours post-transfection. The 
histograms of the BiFC intensity are shown. 
 
 At the 1-to-4 and 1-to-8 ratios, the positive peak has shifted to the left. Since the percentage of 
BiFC positive cells remains constant, it is unlikely that this shift is due to a change in the 
expression of the BiFC plasmids. To verify the level of expression in these samples, we 
performed a Western blot on cell lysates from these co-transfected cells (Figure 18). 
 
Figure 18: Protein expression in Vpr-flag competition assay. Cells were transfected as described in Table 7 and 
collected 18 hours post-transfection for Western blot analysis using α-HA antibody. 
 
The expression of VN-Vpr and VC-Vpr is equivalent in all the cell lysates. With no change in 
Venus-Vpr protein expression between the samples, the shift to the left of the histograms in the 
1-to-4 and 1-to-8 samples cannot be attributed to variation in expression or translation. We 
calculate the mean fluorescence intensity using only the BiFC positive population, so the 
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percentage of BiFC positive cells is not reflected in this measurement. A change in 
strength/intensity of the BiFC signal of individual cells is the most likely explanation of the 
decrease seen in the MFI and histograms. 
 
We next assessed the decrease in BiFC signal intensity using immunostaining followed by 
imaging using a confocal microscope. In order to clearly visualize the differences, the 1-to-8 
ratio of Venus-Vpr to Vpr-flag was used. HeLa cells were grown on coverslips and transfected 
with 100ng Venus-Vpr plasmids (50ng VN-Vpr and 50ng VC-Vpr) with or without Vpr-flag, 
fixed, and stained with anti-Flag antibody (Figure 19). 
 
Figure 19: Fluorescence intensity decreases with the co-transfection of Vpr-flag. Cells were seeded onto 
coverslips and transfected as described. Coverslips were fixed at 20 hours post-transfection, stained with 
monoclonal Flag M5 and Cy5-conjugated secondary antibodies, and viewed with a confocal microscope at 60X 
magnification. 
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The FITC laser PMT was set at a constant voltage of 790 for all images taken in this set to ensure 
an accurate comparison. A visible decrease in BiFC fluorescence intensity was observed in all 
cells co-transfected with Vpr-flag compared with Venus-Vpr alone. A representative set of 
Venus-Vpr and Vpr-flag co-transfected cells is shown circled in white on the merged image. The 
differences in BiFC intensity were quantified using MetaMorph software. The average intensity 
of FITC signal in the nucleus for Venus-Vpr transfection without Vpr-flag (n=4) was 223.34 ± 
47.09. For Vpr-flag co-transfected cells, five separate images containing n=12 co-transfected 
cells were analyzed to generate an average pixel intensity of 141.10 ± 22.85. When we 
normalized to the Venus-Vpr transfection, we found a 37% decrease in pixel intensity. Using 
flow cytometry, we saw a decrease of 30% from Venus-Vpr alone to the 1:8 sample. These 
results complement each other and show that a decrease in oligomerization can be visualized by 
both flow cytometry through mean fluorescence intensity of BiFC positive cells and fluorescence 
microscopy through pixel intensity. 
5.2.4 Summary of Aim #2 
The focus of Aim #2 was to quantify a decrease in oligomerization using bimolecular 
fluorescence complementation. A proof-of-concept experiment was designed that takes 
advantage of the bimolecular nature of the assay, and two expression plasmids were tested under 
this system. HA-Vpr was unable to achieve the desired levels of protein expression, and Vpr-flag 
was used for the final assay. The co-transfection of Vpr-flag produces an initial spike in mean 
fluorescence intensity of BiFC-positive cells, which then steadily decreases as the Vpr-flag 
concentration is increased. The decrease was not attributable to protein expression levels and 
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could be visualized by a shift to the left in the flow histogram and by a decrease in pixel intensity 
in immunofluorescence analysis. 
5.3 AIM #3: TO ASSESS LIBRARIES FOR AN EFFECT ON VPR 
OLIGOMERIZATION 
5.3.1 Initial Toxicity Assessments 
As shown in section 5.1.1.2, cells undergo considerable stress during this assay. The addition of 
an exogenous small molecule will cause additional stress to cells. To ensure that treatment with 
peptide and small molecules was not going to lead to toxicity, it was necessary to optimize two 
parameters: the volume of solvent added into the media and the final small molecule 
concentration in the media. 
5.3.1.1 Volume of DMSO Solvent 
 
Some Vpr peptides and all leucine rotamers were dissolved in DMSO, and high concentrations 
of DMSO are toxic to cells. In order to determine the maximum volume of compound that could 
be added to cells, it was first necessary to test the quantity of DMSO that transfected HeLa cells 
could tolerate. A cytotoxicity assay was performed on transfected cells treated with increasing 
volumes of DMSO (Figure 20). Cell survival was decreased by 15% with the addition of 1μL 
DMSO, and to 20% with the addition of 5μL, whereas 10μL resulted in 80% cell death. We 
elected to use a solvent volume of 2μL when adding peptides and small molecules to wells so 
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that no greater than 20% of cells would be affected by the DMSO solvent alone. With a solvent 
volume of 2μL added into 200μL of media, library members undergo a final dilution of 1 to 100. 
 
Figure 20: DMSO tolerance of transfected HeLa cells. Five hours post-transfection, cells were transferred to a 96 
well plate and DMSO was added to wells in triplicate. At 24 hours post-transfection, cytotoxicity was assessed by 
MTT assay. 
 
5.3.1.2 Concentration of Peptide Library 
 
We next determined the maximum concentration of the Vpr peptide library that transfected cells 
could tolerate. Vpr peptides were dissolved according to the solubility table in Appendix A and 
reconstituted to a concentration of 1 mg/mL, which is the equivalent of 500-600 μM. A final 
concentration of 10 μg/mL of peptide was tested for cell survival by MTT assay (Figure 21). 
  49 
 
Figure 21: Cytotoxicity of peptide library at 10 μg/mL. Transfected cells were treated in triplicate with peptide at 
a concentration of 10 μg/mL and analyzed by MTT assay 24 hours post-transfection. Blue bars represent peptides 
dissolved in PBS, and green bars represent peptides dissolved in DMSO. 
 
No toxicity greater than 20% was seen in the peptides dissolved in PBS. These peptides were 
assayed at a final concentration of 10 μg/mL in all subsequent experiments. DMSO-mediated 
toxicity decreased cell survival by 25%. Even when normalized to the DMSO-treated control, 
peptides 10 and 12-16 exhibited greater than 50% toxicity. These peptides were diluted 1:10 into 
DMSO to maintain solubility and tested at a final concentration of 1 μg/mL (Figure 22).  
 
At 1 μg/mL, no toxicity beyond that attributable to the DMSO solvent was observed in peptides 
10 and 12-15. Peptide 16 showed 25% toxicity compared to the DMSO-treated cells, and 60% 
compared to the untreated cells. As this was the only peptide that showed toxicity at 1 μg/mL 
concentration, we chose to assess the DMSO peptides at the uniform concentration of 1 μg/mL. 
To control for the difference cytotoxicity of the two solvents, the peptides dissolved in PBS were 
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normalized to the untreated control, and the peptides dissolved in DMSO were normalized to the 
DMSO-treated control in all future experiments. 
 
Figure 22: Cytotoxicity of DMSO-dissolved peptides at 1 μg/mL. Transfected cells were treated in triplicate with 
peptide and analyzed by MTT assay 24 hours post-transfection. 
 
5.3.1.3 Concentration of Leucine Rotamer Library 
 
We next determined the maximum concentration of the leucine rotamer library. We received this 
library of 45 small molecules as 10mM stocks dissolved in DMSO. Cytotoxicity was assessed at 
final concentrations ranging from 100nM to 10μM, and 1μM was found to be the highest 
concentration tolerated (Figure 23). 
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Figure 23: Cytotoxicity of leucine rotamer library at 1 μM. Cells were transfected, transferred to 96 well plate 
and treated with 1uM of leucine rotamer. 24 hours post transfection, cells were assessed for toxicity using the MTT 
assay. Absorbance was normalized to the DMSO control, which was taken to be 1. This figure represents one of 3 
independent experiments. 
 
There was less than 20% difference between the untreated control and the DMSO control as 
expected. Relative to the DMSO control, only 5 of the 45 rotamers showed greater than 15% 
toxicity. An addition 1:10 dilution of these five molecules was performed (for a final 
concentration of 100nM) but dilution did not significantly increase the cell survival (data not 
shown). Therefore the leucine rotamer library was screened at a concentration of 1μM per well.  
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5.3.1.4 Assay Parameter Summary 
 
HeLa cells were transfected in a single plate. Five hours post-transfection, cells were moved and 
re-plated into a 96 well plate. Cells were allowed to settle for 15 minutes, then treated with 
library members in triplicate and incubated overnight. Twenty-four hours post-transfection, cells 
were prepared for analysis by flow cytometry or high content image analysis. Peptides dissolved 
in PBS were added to cells at 10 μg/mL (5-6 μM), and peptides dissolved in DMSO were added 
at 1μg/mL (500-600nM). Leucine rotamers were added at 10μM concentrations. 
5.3.2 Flow Cytometry Analysis 
 
Figure 24: Mean fluorescence intensity of peptide-treated cells. Cells were transfected and treated with peptide 
in triplicate at 5 hours post-transfection. Cells were prepared for flow cytometry at 24 hours post-transfection. The 
screen was repeated n=3 times. 
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We started out screening the overlapping Vpr peptide library. Flow cytometry was used to 
generate preliminary data. The mean fluorescence intensity of BiFC-positive cells was 
determined and normalized to the proper solvent control (Figure 24). A greater than 20% 
reduction in BiFC signal was observed with peptides 9 and 16. However, this decrease is directly 
correlated with an increase in the total cells positive for BiFC fluorescence. Furthermore, the 
samples with an increased percentage of positive cells were the result of sample-wide shifts in 
the fluorescence intensity (Figure 25). 
 
Figure 25: Histogram shifts of two peptides. The fluorescence intensities for all the cells were plotted to obtain the 
histogram. Peptide 9 is shown in pink and peptide 16 is red. 
 
The peptides caused a shift to the right of over a log in the negative peak. The positive peak was 
undetectable, but the shifted histogram may just have positive cells that are higher than the 
detection limit of the flow system (an upper limit of 10,000). The peptides that caused histogram 
shifts were found to precipitate and fall out of solution upon addition to cell media, and it is 
likely that the histogram shift is related to this solubility concern. These peptides were 
reconstituted fresh from lyophilized protein and were found to be soluble once more. They were 
aliquoted to reduce the need for multiple freeze/thaw cycles. 
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5.3.3 High Content Imaging Analysis 
In attempts to re-test the newly soluble peptides and screen the leucine rotamer library, it became 
clear that high throughput cytometry was not ideal for running large volumes of large cells. The 
plate reader function of the BD LSRII cytometer contains narrower tubing than the rest of the 
machine, and the tubing routinely became clogged mid-way through a plate. On some occasions 
the machine became completely jammed, and on others the cell counts would vary by over 100% 
as a clump of cells worked its way free. These data sets were disregarded due to cross 
contamination of the results from these cell clumps. Between the high run time per plate under 
ideal (non-clogged) conditions and the frequency of unreliable results, we decided to switch the 
screening method to a high content image-based analysis.  
 
High content screening uses automated fluorescence microscopy coupled to a CCD camera to do 
image-based analysis of intensity. Several features make it more convenient than the flow 
cytometry analysis method, including a shorter run time per plate and less handling of cells 
before analysis. Cells are fixed in individual wells without the need to prepare a cell suspension. 
This eliminates the final trypsinization step before flow cytometry, which reduces cell stress and 
the loss in cell number during centrifugation and washing steps.  
5.3.3.1 Z' factor 
 
In order to determine the power of a high content screen, a few variables must be considered. 
The signal-to-noise ratio measures the resolving power of the assay, or its ability to distinguish 
positive cells from background fluorescence. The Z' factor measures the separation band, a 
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combination of the variability and the difference in mean signal between the positive and 
negative controls [104]. A trial plate consisting of transfected and untransfected cells was 
analyzed to determine the best measure of intensity in future screens. 
 
The signal to noise ratio (S/N) is calculated as: 
 
Our test plate showed a S/N of 46.1 using the Average Nuclear FITC Spot Intensity, and a S/N of 
8.53 using the Average Nuclear FITC Intensity. The signal-to-noise ratio only shows the 
resolving power, so it is necessary to also look at the Z' factor, which is calculated as follows: 
 
By this definition, our test plate showed a Z' factor of 0.447 using the Average Nuclear FITC 
Spot Intensity, and a Z' factor of -0.088 using the Average Nuclear FITC Intensity. The negative 
Z' factor indicates that the separation band is non-existent, either due to resolving power or 
variation between the sample wells. In this case it is the resolving power that is lacking, as 
shown by the small S/N obtained for the Average Nuclear FITC Intensity. Desirable Z' factors 
are in the range of 0.3 to 1. Given the results of these two calculations, the Average Nuclear 
FITC Spot Intensity was chosen as the measure for BiFC fluorescence in future screening plates. 
5.3.3.2 Data Normalization 
 
In order to compare multiple screening plates, each containing replicate wells, a significant 
amount of data manipulation is necessary. Each small molecule is tested in triplicate on each 
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plate. The replicate wells were averaged, and the average between these three wells was used to 
normalize the data between plates. 
 
Based on criteria published by the University of Pittsburgh Drug Discovery Institute, Z scores 
were used to normalize the data across multiple plates [105]. The Z score is calculated as 
follows: 
 
where x is the value to be normalized, μ is the mean, and σ is the standard deviation of the mean. 
This calculation expresses the data in terms of the number of standard variations from the mean. 
For our mean, we use the average across the replicates of the appropriate solvent-treated, 
transfected control. To compare between plates, we averaged the Z scores from individual plates 
for each small molecule. Because we were testing a cell-based screen with no known positive 
control, we set our hit threshold low, requiring standard deviations to fall just one standard 
deviation above or below the mean in order to consider a molecule as a hit. 
5.3.3.3 Analysis of Peptide Library 
 
The overlapping Vpr peptide library was screened n=4 times by high content analysis (Figure 
26). Peptides dissolved in DMSO solvent showed a 70% reduction in cell number in comparison 
to peptides dissolved in PBS (Fig. 26A). While this is a higher level of overall cell loss, the 
percentage of BiFC-positive cells was constant across all wells (Fig 26B). Despite high toxicity 
from the peptides, the frequency of BiFC positive cell was the same and thus they are still able to 
be compared to the rest of the wells. 
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Figure 26: Cell count and BiFC positive cells in high content peptide analysis. Wells were treated with peptide 
in triplicate and analyzed by high content imaging screen. The (A) total cell count per fluorescence microscopy field 
and (B) percentage of BiFC positive cells per well from an example plate are shown. Peptides in blue are dissolved 
in PBS, and peptides in green are dissolved in DMSO. 
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The library of overlapping Vpr peptides was screened by high content analysis n=4 times. Z 
scores were calculated and averaged as seen in section 5.3.3.2 and the average scores from 4 
repetitions were plotted (Figure 27). 
 
Figure 27: Effect of peptide library on nuclear BiFC signal. Peptides were screened for an effect on nuclear 
BiFC fluorescence using high content imaging (n=4). Data was normalized to the solvent-appropriate transfected 
control using Z score methods. The average and standard deviation across 4 repetitions were calculated and plotted. 
 
While five peptides were greater than one standard deviation from the mean BiFC signal 
intensity, all of their standard deviations overlapped the variability window and thus cannot 
definitely be considered a deviation from the mean. Analysis by flow cytometry showed that 
peptides 9 and 16 had the largest negative effect on mean fluorescence intensity of all the 
peptides. Interestingly, high content analysis showed an increase in nuclear fluorescence 
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intensity by peptide 9. Peptide 16 was also found to show a negative effect on nuclear BiFC 
intensity by high content analysis. 
5.3.3.4 Analysis of Leucine Rotamer Library 
 
Figure 28: Effect of leucine rotamer library on nuclear BiFC signal. Small molecules were screened for an 
effect on nuclear BiFC fluorescence using high content imaging (n=2). Data was normalized to the solvent-
appropriate transfected control using Z score methods. The average and standard deviation across repetitions were 
calculated and plotted. 
 
The leucine rotamer library contains 45 small molecules, and it was screened n=2 times using 
high content image analysis for effects on nuclear BiFC signal (Figure 28). Of the 45 leucine 
rotamers screened, three had greater than one standard deviation separation from the mean. 
Rotamer 14 had a separation of +2.23 standard deviations from the transfected control, meaning 
  60 
it increased the mean nuclear BiFC signal. Rotamer 36 also increased nuclear BiFC signal, but 
was less potent (separation of +1.09 standard deviation from the transfected control) than 
rotamer 14. Only rotamer 32 decreased the nuclear BiFC signal by greater than a standard 
deviation. Rotamer 32 showed a separation of -1.37 standard deviations from the mean.  
 
Figure 29: BiFC signal intensity at two concentrations of selected leucine rotamers.  Three leucine rotamers 
were screened for their effect on nuclear BiFC signal at two different concentrations. 
 
These three rotamers were screened again using a 10μM concentration (Figure 29). The positive 
effect of rotamer 14 on BiFC signal was magnified to greater than 3 standard deviations at 
10μM. The negative effect of rotamer 32 remained the same at both concentrations. At the 
original concentration, rotamer 36 treatment resulted in an increase in nuclear BiFC 
fluorescence; however, at the higher concentration a negative effect on nuclear BiFC 
fluorescence was observed. At 10μM, a 67% reduction in cells per field was seen with rotamers 
32 and 36. Rotamer 14 is comparatively less toxic, with just a 20% reduction in cells per field. 
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5.3.4 Summary of Aim #3 
Maximum tolerated concentrations of two small libraries were determined using a MTT cell 
survival assay. The efficacy of the libraries to block Vpr oligomerization was screened using a 
combination of two methods: plate-based flow cytometry and automated fluorescence 
microscopy. Flow cytometry was abandoned for technical reasons, and imaging-based high 
content screening was the final method of analysis. The overlapping Vpr peptide library was 
screened at 5-6μM for peptides dissolved in PBS, and 500-600nM for peptides dissolved in 
DMSO, but no peptides showed a significant deviation from the control BiFC signal. The leucine 
rotamer library was screened at 1μM, and two molecules of interest were identified. One showed 
a concentration-dependent increase in BiFC signal, and the other showed a decrease in BiFC 
signal. 
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6.0  DISCUSSION 
After over 25 years of HIV research, scientists still have not discovered a cure for HIV/AIDS. 
The development of HAART has prolonged the lives of millions of HIV positive patients and 
has reduced the spread of disease, especially through vertical transmission [106]. However, the 
inability to follow this toxic and strict drug regimen, in combination with the high mutation rate 
of HIV-1, leads to the evolution of drug-resistance in patients that ultimately causes HAART to 
fail and patients to succumb to AIDS-related opportunistic infections. 
 
The HIV-1 genome is composed of 9 genes whose products perform structural, enzymatic and 
accessory roles in the viral life cycle. HAART targets HIV-1 enzymes and steps involved in 
replication and entry. Advances in the study of protein-protein interactions (PPI) in the last ten 
years have opened up new lines of research in the field of HIV therapeutics that have shown 
promise in vitro [17, 41, 56]. One specific type of protein-protein interaction, the formation of 
dimers, has been identified as a drug target in almost all HIV proteins [39, 42, 53, 61-63, 107]. 
 
The HIV-1 accessory protein Vpr is multifunctional and affects several host cellular pathways to 
enhance viral replication. It arrests the cell cycle at G2/M, induces apoptosis in bystander cells, 
regulates cellular immune function, causes neuropathogenesis, and is incorporated into new virus 
particles [76, 78, 80, 82]. Vpr incorporation into viral particles indicates that it plays a role in 
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early infection. Vpr has been shown to enhance the infection of macrophages, transactivate the 
viral LTR promoter, and to assist in transport of the pre-integration complex into the nucleus [85, 
93, 108]. Without the presence of Vpr in the virion, the early stages of viral replication could be 
hampered. It has been shown that dimerization-deficient Vpr cannot be incorporated into virus 
particles. The focus of this thesis was two-fold: First, to develop an assay to measure changes in 
Vpr oligomerization and secondly, to screen two libraries for inhibitors of Vpr oligomerization. 
 
Our laboratory had previously created a pair of bimolecular fluorescence complementation 
(BiFC) plasmids for Vpr. When co-transfected, these plasmids produce Vpr fusion proteins that 
restore a fluorescent molecule when the fusion proteins are in close proximity during 
dimerization. Initial studies were performed to determine the optimal cell line and transfection 
reagents with which to visualize this fluorescence complementation. A protocol was devised that 
routinely transfected over half of HeLa cells with both complementation plasmids (Figure 8). 
With the basic parameters of the assay in place, we focused on how to test exogenous molecules 
for an effect on this dimerization. 
 
Our system relies on a large-scale transfection followed by replating into a 96 well plate in order 
to reduce the well-to-well variation in transfection efficiency that accompanies individual 
transfections. This strategy has been implemented successfully in the development of other high 
content screens [109-111]. As the BiFC reaction is irreversible, the timing of the replating and 
compound addition is critical to the success of the assay [69]. We found that our system yielded 
protein expression between 6 and 9 hours post-transfection (Figure 10). Replating and the 
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addition of small molecules were performed at 6 hours post-transfection to ensure that cells had 
time to take up the compounds before protein expression began.  
 
The next focus of our study was to show that the BiFC system could resolve a decrease in Vpr 
oligomerization. Dimerization relies on the secondary and tertiary structure of a protein, not 
specific motifs [65]. As a result, there are no broad-spectrum dimerization inhibitors available, 
nor any that target a general leucine zipper or beta sheet structure. Small molecule inhibitors of 
dimerization tend to be discovered through rational design based off of a crystal structure of a 
protein [112, 113]. There is no crystal structure available for Vpr, nor is there a known inhibitor 
of Vpr dimerization. Of the eight inhibitors of Vpr functions, only two have been shown to bind 
directly to Vpr [97, 98].  
 
In order to detect a decrease in Vpr oligomerization through BiFC signal, we used a competition 
assay. A similar strategy has been used in screening to discover high affinity binders of 
transcription factors [114]. Using a triple transfection strategy, we co-transfected the two Venus-
tagged Vpr plasmids and a Vpr expression plasmid without a BiFC tag. Because all three of the 
plasmids encode full-length Vpr, more non-BiFC configurations of the Vpr dimer are possible 
(Figure 13). At higher input levels of untagged Vpr, a decrease in the mean fluorescence 
intensity (MFI) but not percentage of BiFC-positive cells was observed. This suggested that the 
transfection efficiency was the same among the samples, but that triple plasmid transfected cells 
fluoresce less brightly than cells not transfected with competitor Vpr. We confirmed this through 
immunofluorescence analysis, using the ratio that had given us the highest reduction in MFI 
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(30%) via flow cytometry. Quantitation of the change in spot intensity on the 
immunofluorescence images showed a similar decrease in intensity (27%). 
 
Interestingly, the percentage of BiFC-positive cells in triple plasmid-transfected cells was twice 
that of VC and VN plasmid co-transfected cells (Figure 16A). One possible explanation for this 
is the formation of higher order oligomers. Between the 1:0 sample and the 1:1 sample, the input 
of Vpr-encoding plasmid doubles. Vpr is known to form dimers, trimers and hexamers in a 
concentration-dependent manner [89]. This initial increase was seen regardless of the initial 
input of Venus-Vpr (tested at 100ng, 200ng, and 400ng). 
 
After verifying the quantitative nature of the BiFC system with a competition assay, it was 
necessary to determine the volume and concentration of compound that transfected cells could 
tolerate. HeLa cells tolerated up to 2.5% DMSO in their media, and our screens were designed 
for a maximum addition of 1% DMSO to the media (Figure 20). The peptide library was split 
into two sections depending on their solvent (PBS or DMSO). The peptides dissolved in PBS 
were tolerated at a final concentration of 10μg/mL, or 5-6μM. Peptides dissolved in DMSO were 
tolerated at a 10-fold dilution, 1μg/mL. The leucine rotamer library was tolerated at a final 
concentration of 1μM. With these concentrations determined, we started screening using plate-
based flow cytometry. 
 
Plate-based flow cytometry was able to provide preliminary data on the peptide library, but 
mechanical issues with the plate reader prevented further analysis of the leucine rotamer library. 
Imaging-based high content screening, using automated fluorescence microscopy, has several 
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advantages over flow-based screening. The preparation for flow involves trypsinization and the 
generation of a single cell suspension; this is the third trypsinization in 36 hours in this assay 
protocol. Much less time and labor is needed in the preparation for high content analysis, and the 
addition of nuclear staining provides a measure of cytotoxicity. In practice, however, toxicity 
was observed as a decrease in cells per field, not as nuclear fragmentation. 
 
One important feature of a high content screen is the Z' factor. This measurement takes into 
account the difference between the positive and negative controls in the assay and the variability 
from well-to-well. A sample plate, consisting of untransfected and transfected cells, was run in 
the high content system. Knowing that the BiFC signal is localized in and around the nucleus, the 
list of potential variables was restricted to nuclear FITC intensity. Even with this restriction, 
there were six sets of values from which to choose. The highest Z' factor was 0.447, and it was 
obtained using the average nuclear spot FITC intensity. This variable was used to evaluate the 
remainder of the HCS experiments. 
 
In order to compare multiple plates against each other, the data needed to be normalized. 
Replicates within a single plate were averaged, and the average was normalized to the solvent-
appropriate transfection control. For example, a peptide dissolved in DMSO was normalized to 
transfected cells treated with 1% DMSO.  Z scores were the methodology recommended by the 
Hillman Cancer Center Flow Cytometry core at which the samples were run and the University 
of Pittsburgh Drug Discovery Institute [105]. Z scores present the difference between a value and 
the control in terms of standard deviations from the control mean. The hit threshold of greater 
than one standard deviation from the mean was chosen for three reasons. First, this is a cell-
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based screen and the library members may be impermeable to cells. Secondly, the final 
concentrations of small molecule that we are applying to cells are in the low micromolar range. 
In vitro HTS assays typically discover hits in the high micromolar or millimolar range. The low 
concentration of the small molecule treatment may reduce the magnitude of the result. Third, this 
assay does not have a known positive control, and thus no effective dose is available for 
reference and/or calibration. 
 
The screen of the peptide library (n=4) yielded 5 compounds whose Z score was greater than one 
standard deviation away from the mean, but all 5 had large error bars that extended into the hit 
threshold. The screen of the leucine rotamer library (n=2) yielded three compounds who were 
greater than one standard deviation from the mean and whose error bars did not cross the hit 
threshold (Figure 28). These rotamers (14, 32, and 36) were assessed at a tenfold higher dilution 
of 10uM to further evaluate the effect of higher concentration.. Rotamers 32 and 36 displayed 
67% toxicity at the level, but rotamer 14 remained relatively non-toxic. Rotamer 32 had a 
negative effect on nuclear BiFC intensity, but increasing the concentration of 32 did not increase 
the magnitude of the effect.  
 
Interestingly, 14 shows increased nuclear BiFC fluorescence compared to the control, and it 
responded in a dose-dependent manner when tested at a higher concentration. While this was not 
the desired outcome of the screen, a compound that increases oligomerization of Vpr could have 
laboratory relevance. Vpr-EGFP is used to create fluorescently tagged virus particles for studies 
on viral entry and uncoating. If an increase in Vpr oligomerization results in an increase in 
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incorporation into the viral particle, this small molecule could be used to increase the overall 
intensity of fluorescent virions, which would aid imaging studies. 
 
Taken together, a system to detect the oligomerization of HIV-1 Vpr was developed and 
validated. It is capable of measuring changes in fluorescence intensity through both flow 
cytometry and high content imaging. We concluded that BiFC is a valid system for detecting 
interference with oligomerization and moved forward to a small-scale high content screen. A 
total of 67 members of two libraries were screened for effects on nuclear BiFC intensity, and 
three small molecules with weak but consistent effects were identified. 
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7.0  FUTURE WORK 
Initial studies on HIV-1 oligomerization using the bimolecular fluorescence complementation 
reporter system have resulted in the creation of a transfection-based screening assay. Using the 
HIV-1 Vpr oligomerization assay yielded two compounds that have a weak effect on the nuclear 
fluorescence intensity of the BiFC signal. To further these screening studies: 
 
A transduction system should be created to deliver the Vpr genes. This delivery system would 
eliminate two sources of cell stress. There would be no need for transfection and the cells could 
be seeded directly into a 96 well plate, avoiding the re-plating step. Two lentiviral vectors should 
be created, one for VN-Vpr and one for VC-Vpr. Pseudotyping with VSV-G envelope would 
ensure high transduction. The two vectors would have to be mixed and titrated to determine the 
optimum MOI. By alleviating some of the assay-induced cell stress, small molecules should be 
able to be tested at higher concentrations without causing toxicity-related cell death. 
 
Two small molecules showed an effect on nuclear BiFC signal intensity during the screening 
process. The effect should first be verified via flow cytometry and/or immunofluorescence. Then 
secondary screening should be performed to determine the nature of the effect. The level of Vpr 
expression in small-molecule treated cells should be determined to rule out an effect on 
translation. The effect of the small molecules on BiFC signal intensity using Venus plasmids 
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fused to proteins other than Vpr, such as cJun/Fos should be tested to rule out an effect on 
restoration of the Venus molecule.  
 
Once these small molecules have been verified, further studies could be performed to assess their 
effect on various Vpr functions, specifically the incorporation of Vpr into new viral particles. 
These assays could be done in HEK293T cells through pseudotyping of HIV-1 proviral DNA 
deficient in Vpr (NL4-3ΔVpr or YU-2ΔVpr) with Vpr in the presence of the small molecule, 
then collecting the virus and probing for Vpr with specific antibody by Western blot. As Vpr 
fusions are used to create fluorescent viral particles, a small molecule that shows an increase in 
Vpr incorporation is as useful as one that shows a decrease. 
 
In addition to testing the effect of the identified small molecules on incorporation, structural 
analogs of the lead compounds could be synthesized and tested for improved potency in the 
interference of Vpr oligomerization. Knowledge of the structural motifs that improve or abolish 
effectiveness can help identify the shape of the region to which the small molecule binds. 
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APPENDIX 
VPR PEPTIDE SEQUENCE AND SOLUBILITY INFORMATION 
 
Peptide # Amino Acid Sequence 
Solubility Data 
Water PBS DMSO 
1 MEQAPEDQGPQREPY + + + 
2 PEDQGPQREPYNEWT + + + 
3 GPQREPYNEWTLELL + + + 
4 EPYNEWTLELLEELK + + + 
5 EWTLELLEELKSEAV _ + + 
6 ELLEELKSEAVRHFP + + + 
7 ELKSEAVRHFPRIWL + + + 
8 EAVRHFPRIWLHSLG + + + 
9 HFPRIWLHSLGQHIY + + + 
10 IWLHSLGQHIYETYG _ _ + 
11 SLGQHIYETYGDTWA + + + 
12 HIYETYGDTWAGVEA _ _ + 
13 TYGDTWAGVEAIIRI _ _ + 
14 TWAGVEAIIRILQQL _ _ + 
15 VEAIIRILQQLLFIH _ _ + 
16 IRILQQLLFIHFRIG _ _ + 
17 QQLLFIHFRIGCQHS + _ + 
18 FIHFRIGCQHSRIGI + + + 
19 RIGCQHSRIGIIQQR + + + 
20 QHSRIGIIQQRRARN + + + 
21 IGIIQQRRARNGASR + + + 
22 QQRRARNGASRS + + + 
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